<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="en">Cardiovascular Therapy and Prevention</journal-title><trans-title-group xml:lang="ru"><trans-title>Кардиоваскулярная терапия и профилактика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2021-3106</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3106</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>COVID-19 AND DISEASES OF THE CIRCULATORY SYSTEM</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>COVID-19 И БОЛЕЗНИ СИСТЕМЫ КРОВООБРАЩЕНИЯ</subject></subj-group></article-categories><title-group><article-title>Dynamics of age characteristics and prevalence of concomitant cardiovascular and non-sardiovascular diseases in patients hospitalized with COVID-19 during epidemic wave: data from TARGET-VIP registry</article-title><trans-title-group xml:lang="ru"><trans-title>Динамика возрастных показателей, частоты коморбидных сердечно-сосудистых и некардиальных заболеваний среди больных, госпитализированных по поводу COVID-19, в течение эпидемической волны (данные регистра ТАРГЕТ-ВИП)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5784-4525</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукьянов</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukyanov</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, руководитель отдела клинической кардиологии.</p><p>Москва. Тел.: +7 (916) 702-21-11</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">loukmed@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7717-4362</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марцевич</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Martsevich</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Юрьевич Марцевич — доктор медицинских наук, профессор, руководитель отдела профилактической фармакотерапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9499-4979</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пулин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pulin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Алексеевич Пулин — кандидат медицинских наук, заместитель генерального директора по научной и образовательной деятельности.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6395-2584</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутишенко</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutishenko</surname><given-names>N. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Петровна Кутишенко — доктор медицинских наук, руководитель лаборатории фармакоэпидемиологических исследований отдела профилактической фармакотерапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7167-3067</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреенко</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreenko</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Юрьевна Андреенко — кандидат медицинских наук, старший научный сотрудник отдела клинической кардиологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5603-7038</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воронина</surname><given-names>В. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Voronina</surname><given-names>V. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виктория Петровна Воронина — кандидат медицинских наук, старший научный сотрудник отдела профилактической фармакотерапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6826-860X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Диндикова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dindikova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Валерия Александровна Диндикова — младший научный сотрудник отдела клинической кардиологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8119-9645</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дмитриева</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dmitrieva</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Надежда Анатольевна Дмитриева — кандидат медицинских наук, старший научный сотрудник лаборатории фармакоэпидемиологических исследований отдела профилактической фармакотерапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1493-4544</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загребельный</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagrebelny</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александр Васильевич Загребельный — кандидат медицинских наук, старший научный сотрудник отдела профилактической фармакотерапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9111-8738</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маковеева</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Makoveeva</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Николаевна Маковеева — научный сотрудник отдела клинической кардиологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3299-1078</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лерман</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lerman</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Викторовна Лерман — кандидат медицинских наук, старший научный сотрудник отдела профилактической фармакотерапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7891-3721</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Окшина</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Okshina</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Юрьевна Окшина — кандидат медицинских наук, старший научный сотрудник отдела клинической кардиологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5631-2669</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сгибнева</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sgibneva</surname><given-names>А. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алена Сергеевна Сгибнева — ординатор.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6061-2565</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александр Андреевич Смирнов — лаборант-исследователь отдела клинической кардиологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8169-8919</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Belova</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Екатерина Николаевна Белова — программист, лаборатория биостатистики.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5501-5731</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кляшторный</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Klyashtorny</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владислав Георгиевич Кляшторный — кандидат биологических наук, научный сотрудник лаборатории биостатистики.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2361-7172</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудряшов</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudryashov</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Егор Николаевич Кудряшов — программист лаборатории биостатистики.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5227-0657</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпов</surname><given-names>О. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Karpov</surname><given-names>O. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Олег Эдуардович Карпов — доктор медицинских наук, профессор, член-корр. РАН, генеральный директор.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оксана Михайловна Драпкина — доктор медицинских наук, профессор, член-корр. РАН, директор.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">verannik1@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ Национальный медико-хирургический центр им. Н.И. Пирогова Минздрава России</institution></aff><aff xml:lang="en"><institution>Pirogov National Medical and Surgical Center</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>08</day><month>01</month><year>2022</year></pub-date><volume>20</volume><issue>8</issue><fpage>3106</fpage><lpage>3106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Lukyanov M.M., Martsevich S.Y., Pulin A.A., Kutishenko N.P., Andreenko E.Y., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Zagrebelny A.V., Makoveeva A.N., Lerman O.V., Okshina E.Y., Sgibneva А.S., Smirnov A.A., Belova E.N., Klyashtorny V.G., Kudryashov E.V., Karpov O.E., Drapkina O.M., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Лукьянов М.М., Марцевич С.Ю., Пулин А.А., Кутишенко Н.П., Андреенко Е.Ю., Воронина В.П., Диндикова В.А., Дмитриева Н.А., Загребельный А.В., Маковеева А.Н., Лерман О.В., Окшина Е.Ю., Сгибнева А.С., Смирнов А.А., Белова Е.Н., Кляшторный В.Г., Кудряшов Е.Н., Карпов О.Э., Драпкина О.М.</copyright-holder><copyright-holder xml:lang="en">Lukyanov M.M., Martsevich S.Y., Pulin A.A., Kutishenko N.P., Andreenko E.Y., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Zagrebelny A.V., Makoveeva A.N., Lerman O.V., Okshina E.Y., Sgibneva А.S., Smirnov A.A., Belova E.N., Klyashtorny V.G., Kudryashov E.V., Karpov O.E., Drapkina O.M.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3106">https://cardiovascular.elpub.ru/jour/article/view/3106</self-uri><abstract><sec><title>Aim</title><p>Aim. According to hospital-based registry, to evaluate the age characteristics and prevalence of concomitant cardiovascular and non-сardiovascular diseases in patients hospitalized with COVID-19 during epidemic wave.</p></sec><sec><title>Material and methods</title><p>Material and methods. The TARGET-VIP register included 1130 patients aged 57,5+12,8 years (men, 51,2%) hospitalized at the Pirogov National Medical and Surgical Center from April 6, 2020 to June 22, 2020 with COVID-19. Cardiovascular diseases (CVDs) were diagnosed in 51,6% of patients, non-сardiovascular chronic diseases — in 48,6%, while CVDs and/or non-сardiovascular chronic diseases — in 65,8% of patients.</p></sec><sec><title>Results</title><p>Results. The average age of patients significantly increased by an average of 0,77 years per week (p&lt;0,001), while the difference between the 1st week (52,8 years) and 11th week (62,2 years) was 9,4 years; the proportion of men did not change significantly. The proportion of patients with CVDs increased significantly — from 34,2% to 66,7%, on average by 3,7% per week (p&lt;0,001; Incidence Risk Ratio (IRR)=1,037; 95% confidence interval (CI), 1,017-1,058), with chronic non-cardiovascular diseases — from 32,5% to 43,2%, on average by 2,5% per week (p&lt;0,001; IRR=1,025; 95% CI, 1,002-1,049), as well as those with CVDs and/or chronic non-cardiovascular diseases — from 47,5% to 75,3%, on average by 3,2% per week (p&lt;0,001; IRR=1,032; 95% CI, 1,017-1,048). Over the entire period, the proportion of people with hypertension (HTN) was 47,0%, with coronary artery disease (CAD) — 15,4%, with heart failure (HF) — 4,0%, and with atrial fibrillation (AF) — 10,1%. The proportion of patients with HTN increased by 9,5% (p&lt;0,001; OR=1,095; 95% CI, 1,047-1,144), with СAD — by 9,4% (p=0,01; OR=1,094; 95% CI, 1,022-1,172) and with AF — by 9,4% (p&lt;0,001; OR=1,094; 95% CI, 1,023-1,170) per week. The proportion of patients with diabetes was 16,5%, with respiratory diseases — 11,4%, with chronic kidney disease (CKD) — 12,6%, with digestive diseases — 22,5%, with obesity — 6,1%. During the epidemic wave, the most pronounced increase in the proportion of patients with CKD was by 6,2% (p=0,036; OR=1,062; 95% CI, 1,004-1,124) and with digestive diseases — by 6,0% (p=0,01; OR=1,060; 95% CI, 1,014-1,109) per week.</p></sec><sec><title>Conclusion</title><p>Conclusion. According to the 11-week TARGET-VIP registry, the age of patients increased by 9,4 years, CVD cases — by 1,9 times (mainly HTN, CAD, AF), and chronic non­сardiovascular pathology — by 1,3 times (mainly CKD and digestive diseases). These trends in hospital practice corresponded to a weekly increase in the proportion of patients with a higher risk of fatal and non-fatal complications, which is the basis for further research in order to develop a system for a comprehensive prognostic assessment of the degree and rate of increase in the load on hospitals during COVID-19 epidemic wave.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Оценить динамику возрастных показателей, частоты коморбидных сердечно-сосудистых и некардиальных заболеваний у больных, госпитализированных с COVID-19 (COronaVIrus Disease 2019) в период эпидемической волны, по данным госпитального регистра.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В регистр ТАРГЕТ-ВИП (проспекТивный госпитАльный РеГистр пациЕнТов с предполагаемыми, либо подтвержденными коронаВИрусной инфекцией и внебольничной Пневмонией) включены 1130 пациентов, госпитализированных в НМХЦ им. Н. И. Пирогова с 06.04.2020г по 22.06.2020г с COVID-19, в возрасте 57,5+12,8 лет (51,2% мужчин). Сердечно-сосудистые заболевания (ССЗ) были диагностированы у 51,6%, некардиальные хронические заболевания — у 48,6%, а ССЗ и/или некардиальные хронические заболевания — у 65,8% пациентов.</p></sec><sec><title>Результаты</title><p>Результаты. Среди поступавших в стационар пациентов с каждой нед. возрастало число лиц старшего возраста: средний возраст пациентов значимо увеличивался на 0,77 года в нед. (p&lt;0,001), при этом разница между 1-й нед. (52,8 года) и 11-й нед. (62,2 года) составила 9,4 лет; доля мужчин существенно не изменялась. Значимо возрастала доля пациентов с ССЗ — с 34,2 до 66,7%, в среднем, на 3,7% в нед. (p&lt;0,001; Incidence Risk Ratio (IRR)=1,037; 95% доверительный интервал (ДИ): 1,017-1,058), с хроническими некардиальными заболеваниями — с 32,5 до 43,2%, в среднем, на 2,5% в нед. (p&lt;0,001; IRR=1,025; 95% ДИ: 1,002-1,049) и с ССЗ и/или хроническими некардиальными заболеваниями — с 47,5 до 75,3%, в среднем, на 3,2% в нед. (p&lt;0,001; IRR=1,032; 95%ДИ: 1,017-1,048). За весь период доля лиц с артериальной гипертонией (АГ) составила 47,0%, с ишемической болезнью сердца (ИБС) — 15,4%, с хронической сердечной недостаточностью — 4,0% и с фибрилляцией предсердий (ФП) — 10,1%. Доля пациентов с АГ увеличивалась на 9,5% (р&lt;0,001; отношение шансов (ОШ)=1,095; 95% ДИ: 1,047-1,144), с ИБС — на 9,4% (р=0,01; ОШ=1,094; 95% ДИ: 1,022-1,172) и с ФП — на 9,4% (р&lt;0,001; ОШ=1,094; 95% ДИ: 1,023-1,170) в нед. Доля пациентов с сахарным диабетом составила 16,5%, с болезнями органов дыхания — 11,4%, с хронической болезнью почек (ХБП) — 12,6%, с болезнями органов пищеварения (БОП) — 22,5%, с ожирением — 6,1%. В течение эпидемической волны был наиболее выраженным рост доли пациентов с ХБП — на 6,2% (р=0,036; ОШ=1,062; 95% ДИ: 1,004-1,124) и с БОП — на 6,0% (р=0,01; ОШ=1,060; 95% ДИ: 1,014-1,109) в нед.</p></sec><sec><title>Заключение</title><p>Заключение. По данным регистра ТАРГЕТ-ВИП за 11 нед. эпидемической волны возраст пациентов увеличился на 9,4 лет, случаи ССЗ — в 1,9 раза (преимущественно АГ, ИБС, ФП) и хроническая некардиальная патология — в 1,3 раза (преимущественно ХБП и БОП). Эти тренды в госпитальной практике соответствовали еженедельному повышению доли пациентов с более высоким риском развития фатальных и нефатальных осложнений, что является основанием для дальнейших исследований с целью разработки системы комплексной прогностической оценки степени и скорости возрастания нагрузки на стационары в ходе развития эпидемической волны COVID-19.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>новая коронавирусная инфекция</kwd><kwd>COVID-19</kwd><kwd>госпитальный регистр</kwd><kwd>возрастные и гендерные характеристики</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>хронические некардиальные заболевания</kwd><kwd>коморбидность</kwd><kwd>понедельная динамика</kwd><kwd>эпидемическая волна</kwd></kwd-group><kwd-group xml:lang="en"><kwd>coronavirus disease 2019</kwd><kwd>COVID-19</kwd><kwd>hospital-based registry</kwd><kwd>age and sex characteristics</kwd><kwd>cardiovascular diseases</kwd><kwd>chronic non-сardiovascular diseases</kwd><kwd>comorbidity</kwd><kwd>weekly dynamics</kwd><kwd>epidemic wave</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The pandemic of coronavirus disease 2019 (COVID-19) has claimed the lives of more than 5 million people and damaged the economic and social life of the entire world community. Every week, millions of new cases continue to be registered worldwide [<xref ref-type="bibr" rid="cit1">1</xref>][<xref ref-type="bibr" rid="cit2">2</xref>]. At the same time, age, concomitant cardiovascular (CVD) and non-cardiovascular diseases have an important prognostic value in COVID-19 patients [3- 10]. However, in this category of patients, the dynamics of age and sex characteristics, the detection rate of concomitant CVD and non-cardiovascular diseases during the epidemic wave of COVID-19, in particular, among hospitalized patients, have been little studied. The TARGET-VIP prospective in-hospital registry created in Russia makes it possible to study the clinical and anamnestic characteristics, structure and dynamics of comorbidity in patients with COVID-19 during the epidemic wave.</p><p>Based on the foregoing, the aim of the study was to evaluate the age characteristics and prevalence of concomitant cardiovascular and non-cardiovascular diseases in patients hospitalized with COVID-19 during epidemic wave.</p></sec><sec><title>Material and methods</title><p>The TARGET-VIP registry includes 1130 patients hospitalized at the Pirogov National Medical and Surgical Center from April 6, 2020 to June 22, 2020 due to COVID-19 (age, 57,5±12,8 years; men, 51,2%). Concomitant CVDs was diagnosed in 51,6% of patients, while chronic non-CVDs — in 48,6%, CVDs and/or nonCVDs — in 65,8%. At 11-week enrollment period, corresponding to the epidemic wave in Moscow, the number of new COVID-19 cases in Moscow on April 6, 2020 and June 22, 2020 was 691 and 662, respectively, and the maximum number (6703 cases) was registered on May 07, 2020. The weekly dynamics of average patient age and the proportion of following CVDs was assessed: hypertension (HTN); coronary artery disease (CAD); heart failure (HF); atrial fibrillation (AF); prior myocardial infarction (MI) and stroke. The dynamics of the proportion of following chronic non-CVDs was also assessed: diabetes, respiratory diseases (RDs), chronic kidney disease (CKD), digestive diseases (DDs), anemia, and obesity.</p><p>Descriptive statistics were used for statistical data processing. Numerical data are presented as M±SD or Me [Q25%; Q75%]. The statistical significance of differences in numerical data was assessed using the Student’s test, while categorical data — using the χ2 test. For assessing weekly dynamics, regression analysis was used. For binary variables (sex, presence of certain diseases), logistic regression was used with an odds ratio (OR) and 95% confidence interval (CI). For data on the number of certain diseases (number of CVDs, chronic non-CVDs or their sum), Poisson regression was used with an Incidence Risk Ratio (IRR) and corresponding 95% CI. Sex and age of patients were included as covariates in the regression models. Differences were considered significant at p&lt;0,05. Statistical processing was performed using Statistica 7.0 and Stata 15.0 software.</p></sec><sec><title>Results</title><p>The dynamics of age, sex characteristics and comorbidities in patients admitted is presented in Table 1. The mean age of patients over 11-week period increased significantly, on average, by 0,77 years per week, while this parameter for the first (52,8 years) and 11th weeks (62,2 years) differed by 9,4 years. The proportion of men did not change significantly during the followup, with a maximum of 56,3% in the first week and a minimum of 48,2% in the 11th week (p=0,145; OR=0,973; 95% CI: 0,938-1,009). From the 1st to the 11th week of the inclusion period, the proportion of people with CVDs increased by 1,9 times, with chronic non-CVDs — by 1,3 times, and with both types of pathology — by 1,6 times.</p><p>The proportion of patients with CVDs increased significantly, with the CVD number per patient increasing by an average of 3,7% per week (p&lt;0,001; IRR=1,037; 95% CI: 1,017-1,058). The proportion of patients with CVD was the lowest in the 1st week (34,2%) and the highest during the 8th and 11th weeks (68,9 and 66,7%). The average number of chronic nonCVDs per patient significantly increased by 2,5% per week (p&lt;0,001; IRR=1,025; 95% CI: 1,002-1,049). The proportion of patients with CVD and/or chronic nonCVDs increased from 47,5 to 75,3% during the analyzed period. The mean number of CVDs and/or chronic non-CVDs increased by 3,2% per week (p&lt;0,001; IRR=1,032; 95% CI: 1,017-1,048).</p><p>Over the entire period of epidemic wave, the proportion of people with hypertension, on average, was 47,0%, with CAD without MI — 15,4%. At the same time, the proportion of patients with prior MI and stroke averaged 5,0 and 4,0%, while the proportion of patients with CAD and AF was 4,0 and 10,1%, respectively. Dynamics of CVD detection rate in analyzed patients during the study period is presented in Table 2. During the epidemic wave from the 1st to the 11th week, the most pronounced increase was noted in patients HTN (from 30,0 to 64,2%, i.e. 2,1 times; p&lt;0,001), CAD (from 13,2 to 37,3%, i.e. 2,8 times; p&lt;0,001) and AF (from 7,1 to 21,0%, i.e. 3,0 times; p&lt;0,001). The proportion of patients with HTN per week increased on average by 9,5% (p&lt;0,001; OR=1,095; 95% CI: 1,047-1,144), with CAD without MI — by 9,4% (p=0,01; OR=1,094; 95% CI: 1,022-1,172) and with AF by 9,4% (p&lt;0,001; OR=1,094; 95% CI: 1,023-1,170). There was no significant weekly increase in the proportion of patients with CAD who underwent MI and stroke (p&gt;0,05).</p><p>During 11-week period, the proportion of patients with diabetes, on average, was 16,5%, with respiratory diseases — 11,4%, with CKD — 12,6%, with DDs — 22,5%, with anemia — 3,5%, and with obesity — 6,1%. The dynamics of the detection rate of chronic non-CVDs is presented in Table 3. Of the analyzed chronic non-CVDs, to the greatest extent for 11-week period the proportion of patients with CKD (from 6,7 to 19,8%, i.e. 3,0 times; p&lt;0,001) and DDs (from 14,6 to 24,7%, i.e. in 1,7 times; p=0,037) increased. During the epidemic wave, the most pronounced increase in the proportion of patients with DDS was noted. The proportion of CKD patients increased by an average of 6,2% per week (p=0,036; OR=1,062; 95% CI: 1,004- 1,124), and those with CKD increased by 6,0% (p=0,01; OR=1,060; 95% CI: 1,014-1,109). There was no significant weekly increase in the proportion of patients with diabetes, RDs, anemia and obesity (p&gt;0,05).</p><fig id="fig-1"><caption><p>Table 1</p><p>Dynamics of age, sex characteristics and noncommunicable diseases in patients admitted to the center for COVID-19 and community-acquired pneumonia during the enrollment period</p><p>Note: OR (for “proportion of men”), β — «coefficient β» (for “age”), IRR (for “proportion of patients with CVD”, “proportion of patients with non-CVD” and for a combination of these parameters). CI — confidence interval, OR — odds ratio, CVD — cardiovascular diseases.</p></caption><graphic xlink:href="cardiovascular-20-8-g001.jpeg"><uri content-type="original_file">https://cdn.elpub.ru/assets/journals/ojs-dev/2018/1/xafb42hq0fVKJjau0JfbnMId8PCv9HwJn6EIakb1.jpeg</uri></graphic></fig><fig id="fig-2"><caption><p>Table 2</p><p>Dynamics of CVD detection rate in patients admitted to the center for COVID-19 and community-acquired pneumonia during the enrollment period</p><p>Note: CVA — all cases of MI and transient ischemic attack. MI and CVA is taken into account on the date of hospitalization; MI and CVA developed in the hospital are not taken into account. HTN — hypertension, CI — confidence interval, CAD — coronary artery disease, MI — myocardial infarction, CVA — cerebrovascular accident, OR — odds ratio, AF — atrial fibrillation, HF — heart failure.</p></caption><graphic xlink:href="cardiovascular-20-8-g002.jpeg"><uri content-type="original_file">https://cdn.elpub.ru/assets/journals/ojs-dev/2018/1/5uh8lkFCC0acKKPwdI30BBNH7vxchzPS2DLs6sAF.jpeg</uri></graphic></fig><fig id="fig-3"><caption><p>Table 3</p><p>Dynamics of non-CVD detection rate in patients admitted to the center for COVID-19 and community-acquired pneumonia during the enrollment period</p><p>Note: RD — respiratory diseases, DD — digestive diseases, CI — confidence interval, OR — odds ratio, CKD — chronic kidney disease.</p></caption><graphic xlink:href="cardiovascular-20-8-g003.jpeg"><uri content-type="original_file">https://cdn.elpub.ru/assets/journals/ojs-dev/2018/1/W8ubiutthkXzfpMJkAOFX6CO3o5IP2Q360NYlCLz.jpeg</uri></graphic></fig></sec><sec><title>Discussion</title><p>Monitoring of COVID-19 patients in a pandemic, according to published data, revealed that the severity of its clinical course increases with older patients, and the prognosis in the studied cohorts of patients worsens not only with an increase in the proportion of elderly patients, but also with an increase in the proportion of people with CVD and/or chronic non-CVDs (in particular, with diabetes, respiratory diseases, DDs, cancer, obesity) [6-9][<xref ref-type="bibr" rid="cit11">11</xref>][<xref ref-type="bibr" rid="cit12">12</xref>]. In addition, as with other respiratory tract infections, COVID-19 can not only worsen the course of CVD and non-CVDs, but also lead to cardiovascular events [<xref ref-type="bibr" rid="cit6">6</xref>][13-17].</p><p>TARGET-VIP registry revealed a significant weekly increase in the age and detection rate of concomitant CVDs and non-CVDs over 11-week inclusion period, which largely corresponded to the dates of the most pronounced part of COVID-19 wave. Thus, with each subsequent week of the inclusion period during the epidemic wave among hospitalized patients, the risk of fatal and non-fatal complications increased. This is an unfavorable factor, since severe patients are not only more difficult to treat [<xref ref-type="bibr" rid="cit2">2</xref>][<xref ref-type="bibr" rid="cit17">17</xref>][<xref ref-type="bibr" rid="cit18">18</xref>], but they also have a longer length of hospital stay [<xref ref-type="bibr" rid="cit4">4</xref>][<xref ref-type="bibr" rid="cit5">5</xref>][7-9]. The above together leads to a progressive increase in the hospital load during the epidemic wave of COVID-19 [<xref ref-type="bibr" rid="cit2">2</xref>][<xref ref-type="bibr" rid="cit17">17</xref>][<xref ref-type="bibr" rid="cit18">18</xref>]. Perhaps one of the reasons for this is that at the beginning of epidemic, predominantly more mobile and young people were infected, from which older members of their families and labor collectives subsequently became infected, significant part of whom had higher prevalence of noncommunicable diseases.</p><p>A more detailed analysis of the severity and rates of increase in the risk of fatal and non-fatal complications in patients hospitalized with COVID-19 will, in the future, make it possible to predict an increase in hospital load with each subsequent week of the epidemic wave. It seems very important to compare data over the epidemic wave period on the dynamics of age and detection rate of significant comorbidities in specific hospitals in certain cities and regions as a whole, in particular for Moscow. If a significant correlation is found in a particular hospital and in a corresponding region, there will be an additional opportunity to predict the hospital load in the context of subsequent epidemic waves in order to optimize inpatient care. This is the subject of further research.</p></sec><sec><title>Conclusion</title><p>According to the 11-week TARGET-VIP registry, the age of patients increased by 9,4 years, CVD cases — by 1,9 times (mainly HTN, CAD, AF), and chronic non-сardiovascular pathology — by 1,3 times (mainly CKD and digestive diseases). These trends in hospital practice corresponded to a weekly increase in the proportion of patients with a higher risk of fatal and non-fatal complications, which is the basis for further research in order to develop a system for a comprehensive prognostic assessment of hospital load during COVID-19 epidemic wave.</p><p>Relationships and Activities: none.</p></sec></body><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. COVID-19 Weekly Epidemiological Update, 30 November 2021 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2021).</mixed-citation><mixed-citation xml:lang="en">World Health Organization. COVID-19 Weekly Epidemiological Update, 30 November 2021 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2021).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации Министерства здравоохранения РФ. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 13.1 от 1711.2021. М.: Минздрав России; 2021.</mixed-citation><mixed-citation xml:lang="en">Temporary methodological recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 13.1 of 1711.2021. M. 2021. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Дроздова Л. Ю., Бойцов С. А. и др. Временные методические рекомендации: “Оказание амбулаторно-поликлинической медицинской помощи пациентам с хроническими заболеваниями, подлежащими диспансерному наблюдению, в условиях пандемии COVID-19”. Профилактическая медицина. 2020;23(3):2004-41. doi:10.17116/profmed2020230324.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Drozdova LYu, Boitsov SA, et al. Temporary methodological recommendations: “Provision of outpatient medical care to patients with chronic diseases subject to dispensary monitoring in the context of the COVID-19 pandemic”. The Russian Journal of Preventive Medicine. 2020;23(3):2004-41. (In Russ.) doi:10.17116/profmed2020230324.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Карпов О. Э., Лукьянов М. М. и др. Опыт создания и первые результаты проспективного госпитального регистра пациентов с предполагаемыми или подтвержденными коронавирусной инфекцией (COVID-19) и внебольничной пневмонией (ТАРГЕТ-ВИП). Профилактическая медицина. 2020;23(8):6-13. doi:10.17116/profmed2020230816.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Karpov OE, Loukianov MM, et al. Experience of creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP). The Russian Journal of Preventive Medicine. 2020;23(8):6-13. (In Russ.) doi:10.17116/profmed2020230816.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Карпов О. Э., Лукьянов М. М. и др. Проспективный госпитальный регистр больных с предполагаемыми или подтвержденными коронавирусной инфекцией COVID-19 и внебольничной пневмонией (ТАРГЕТ-ВИП): характеристика включенных больных и оценка исходов стационарного этапа лечения. Кардиоваскулярная терапия и профилактика. 2020;19(6):2727. doi:10.15829/1728­8800­2020­2727.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Karpov OE, Loukianov MM, et al. Prospective in-hospital registry of patients with suspected or documented COVID-19 infection and community acquired pneumonia (TARGET-VIP): characteristics of patients and assessment of in-hospital outcomes. Cardiovascular Therapy and Prevention. 2020;19(6):2727 (In Russ.) doi:10.15829/1728­8800­2020­2727.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Конради А. О., Виллевальде С. В., Дупляков Д. В. и др. Открытое наблюдательное многоцентровое исследование (регистр) больных, перенесших новую коронавирусную инфекцию (COVID­19) с поражением сердечно­сосудистой системы или на фоне тяжелой патологии сердечно­сосудистой системы: обоснование, дизайн, значение для клинической практики. Российский кардиологический журнал. 2021;26(1):4287. doi:10.15829/1560­4071­2021­4287.</mixed-citation><mixed-citation xml:lang="en">Konradi AO, Villevalde SV, Duplyakov DV, et al. An open­label multicenter observational study (registry) of patients recovered from coronavirus disease 2019 (COVID­19) with involvement of the cardiovascular system or with baseline severe cardiovascular diseases: rationale, design, and implications for clinical practice. Russian Journal of Cardiology. 2021;26(1):4287. (In Russ.) doi:10.15829/1560­4071­2021­4287.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г. П., Тарловская Е. И., Арутюнов А. Г. и др. Международный регистр “Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS­CoV­2 (AКТИВ SARS­CoV­2)”: анализ 1000 пациентов. Российский кардиологический журнал. 2020;25(11):4165. doi:10.15829/1560­4071­2020­4165.</mixed-citation><mixed-citation xml:lang="en">Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. International register “Dynamics analysis of comorbidities in SARS­CoV­2 survivors” (AKTIV SARS­CoV­2): analysis of 1,000 patients. Russian Journal of Cardiology. 2020;25(11):4165. (In Russ.) doi:10.15829/1560­4071­2020­4165.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г. П., Тарловская Е. И., Арутюнов А. Г. и др. Международный регистр “Анализ динамики Коморбидных заболеваний у пациенТов, перенесшИх инфицироВание SARS­CoV­2” (AКТИВ SARS­CoV­2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции. Российский кардиологический журнал. 2021;26(4):4470. doi:10.15829/1560­4071­2021­4470.</mixed-citation><mixed-citation xml:lang="en">Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. International register “Dynamics analysis of comorbidities in SARSCoV­2 survivors” (AKTIV SARS­CoV­2): analysis of predictors of short­term adverse outcomes in COVID­19. Russian Journal of Cardiology. 2021;26(4):4470. (In Russ.) doi:10.15829/1560­4071­2021­4470.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г. П., Тарловская Е. И., Арутюнов А. Г. и др. Международный регистр “Анализ динамики Коморбидных заболеваний у пациентов, перенесшИх инфицироВание SARSCoV-2” (ДКТИВ) и регистр “Анализ госпитализаций Коморбидных пациентов Инфицированных в период второй волны SARSCoV-2” (АКТИВ SARS-CoV-2). Российский кардиологический журнал. 2021;26(3):4358. doi:10.15829/1560-4071-2021-4358.</mixed-citation><mixed-citation xml:lang="en">Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. International register “Dynamics analysis of comorbidities in SARS­CoV­2 survivors” (AKTIV) and the register “Analysis of hospitalizations of comorbid patients infected during the second wave of SARSCoV­2 outbreak” (AKTIV). Russian Journal of Cardiology. 2021;26(3):4358. (In Russ.) doi:10.15829/1560-4071-2021-4358.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17:135-49. doi: 10.1038/s41574-020-00462-1.</mixed-citation><mixed-citation xml:lang="en">Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17:135-49. doi: 10.1038/ s41574-020-00462-1.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430-6. doi:10.1038/s41586-020-2521-4.</mixed-citation><mixed-citation xml:lang="en">Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430-6. doi:10.1038/s41586-020-2521-4.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mehra MR, Desai SS, Kuy SR, et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020;382(26):2582. doi:10.1056/NEJMoa2007621.</mixed-citation><mixed-citation xml:lang="en">Mehra MR, Desai SS, Kuy SR, et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020;382(26):2582. doi:10.1056/NEJMoa2007621.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Wang Z, Tse G, et al. Cardiac arrhythmias in patients with COVID-19. J Arrhythm. 2020;36(5):827-36. doi: 10.1002/joa3.12405.</mixed-citation><mixed-citation xml:lang="en">Wang Y, Wang Z, Tse G, et al. Cardiac arrhythmias in patients with COVID-19. J Arrhythm. 2020;36(5):827-36. doi: 10.1002/joa3.12405.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fun Q, Zhu H, Zhao J, et al. Risk factors for myocardial injury in patients with coronavirus disease 2019 in China. ESC Heart Fail. 2020;10.1002/ehf2.13022. doi:10.1002/ehf2.13022.</mixed-citation><mixed-citation xml:lang="en">Fun Q, Zhu H, Zhao J, et al. Risk factors for myocardial injury in patients with coronavirus disease 2019 in China. ESC Heart Fail. 2020;10.1002/ehf2.13022. doi:10.1002/ehf2.13022.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто Е. В., Конради А. О., Виллевальде С. В. и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. doi:10.15829/1560-4071-2020-3-3801.</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, Konradi AO, Villevalde SV, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russ.) doi:10.15829/1560-4071-2020-3-3801.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Бубнова М. Г., Шляхто Е. В., Аронов Д. М. и др. Новая коронавирусная инфекционная болезнь COVID-19: особенности комплексной кардиологической и респираторной реабилитации. Российский кардиологический журнал. 2021;26(5):4487 doi:10.15829/1560-4071-2021-4487</mixed-citation><mixed-citation xml:lang="en">Bubnova MG, Shlyakhto EV, Aronov DM, et al. Coronavirus disease 2019: features of comprehensive cardiac and pulmonary rehabilitation. Russian Journal of Cardiology. 2021;26(5):4487. (In Russ.) doi:10.15829/1560-4071-2021-4487</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Камалов А. А., Мареев В. Ю., Орлова Я. А. Концептуальные подходы к поиску эффективного лечения новой коронавирусной инфекции на разных этапах. Вестник Российской академии медицинских наук. 2021;76(1):43-50. doi:10.15690/vramn1402.</mixed-citation><mixed-citation xml:lang="en">17 Kamalov AA, Mareev VY, Orlova IA. Conceptual approaches to finding effective treatment for a new coronavirus infection at different stages. Annals of the Russian academy of medical sciences. 2021;76(1):43-50. (In Russ.) doi:10.15690/vramn1402.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачева О. Н., Котовская Ю. В., Алексанян Л.А. и др. Новая коронавирусная инфекция SARS-CoV-2 у пациентов пожилого и старческого возраста: особенности профилактики, диагностики и лечения. Согласованная позиция экспертов Российской ассоциации геронтологов и гериатров. Кардиоваскулярная терапия и профилактика. 2020;19(3):2601. doi:10.15829/1728-8800-2020-2601.</mixed-citation><mixed-citation xml:lang="en">Tkacheva ON, Kotovskaya YuV, Aleksanyan LA, et al. Novel coronavirus infection SARSCoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020;19(3):2601. (In Russ.) doi:10.15829/1728-8800-2020-2601.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
